Sign In
Buy QBIO
$0.0001
+0 (+0%)
At Close: Jun 02, 2026
Q Biomed (OTCMKTS:QBIO) vs. GeneDx (NASDAQ:WGS) Financial Comparison
01:35am, Sunday, 05'th Apr 2026
GeneDx (NASDAQ: WGS - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the streng
Establishment Labs (NASDAQ:ESTA) & Q Biomed (OTCMKTS:QBIO) Critical Contrast
01:15am, Tuesday, 10'th Feb 2026
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses base
Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review
02:26am, Monday, 19'th Jan 2026
Auna (NYSE: AUNA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of
Q Biomed (OTCMKTS:QBIO) & GoodRx (NASDAQ:GDRX) Financial Survey
02:18am, Saturday, 03'rd Jan 2026
Q Biomed (OTCMKTS:QBIO - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the st
SBC Medical Group (NASDAQ:SBC) and Q Biomed (OTCMKTS:QBIO) Head-To-Head Contrast
02:08am, Wednesday, 10'th Dec 2025
Q Biomed (OTCMKTS:QBIO - Get Free Report) and SBC Medical Group (NASDAQ: SBC - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies bas
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
09:05am, Friday, 14'th Apr 2023
Q BioMed Inc. (OTCQB:QBIO) said it has received a patent in the US and a notice of allowance in Europe for the Uttroside B chemotherapeutic asset, adding to the already issued patents in Korea, C
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
09:21am, Friday, 10'th Feb 2023
Q BioMed Inc. (OTCQB:QBIO) has received a notice of an allowable patent from the US Patent Office related to its liver cancer treatment Uttroside B. The company already holds patents in Korea, Canada
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
11:09am, Monday, 14'th Nov 2022
Q BioMed Inc has given itself a big shot in the arm, adding a multi-million dollar asset in the form of an equity stake in long term partner Mannin Research, which has a drug development pipeline pois
Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment
09:46am, Tuesday, 27'th Sep 2022
Q BioMed Inc. (OTCQB:QBIO) said it has received a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differenti
Q BioMed reports Strontium89 sales revenue surge in shareholder update
10:43am, Friday, 29'th Jul 2022
Q BioMed Inc said it has seen an uptick in sales revenue from Strontium89, the company's potential chemotherapeutic drug, in its recently reported quarter. The company's second-quarter sales revenue
Q BioMed says new publication shows superior safety and efficacy of Uttroside-B versus FDA approved drug Sorafenib
10:10am, Tuesday, 26'th Jul 2022
Q BioMed Inc has highlighted that its pre-clinical Uttroside-B chemotherapeutic to treat liver cancer has been found in a new study to show superior safety and efficacy compared to the current FDA app
Q BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar markets
10:41am, Friday, 06'th May 2022
Q BioMed Inc told investors that it had studiously avoided biotech single-asset risks by acquiring multiple assets over time, across a broad spectrum of indications in large markets and its strategy w
Q BioMed announces publication of research supporting efficacy and development of its Uttroside-B chemotherapeutic to treat liver cancer
09:44am, Wednesday, 16'th Mar 2022
Q BioMed Inc. (OTCQB:QBIO) has announced a new publication in the Frontiers of Oncology journal supporting the efficacy and further development of its Uttroside-B (Utt-B) chemotherapeutic to treat liv
Q BioMed outlines strategic direction and goals for 2022
01:21pm, Monday, 14'th Feb 2022
Q BioMed Inc has outlined its strategic directions and goals for 2022 that call for increasing revenues as the biotech seeks to monetize its current pipeline of products and platforms. “From incep
Q BioMed says it is seeing a ‘significant uptrend' in revenues as it continues to roll out Strontium89
04:52pm, Thursday, 16'th Dec 2021
Q BioMed Inc. (OTCQB:QBIO) told shareholders that the company was seeing a significant uptrend in revenues, advancing its pipeline of assets, and was looking at an imminent up listing to the tech-domi
